Latest news with #NVAX
Business Insider
2 days ago
- Business
- Business Insider
Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses'
Novavax (NVAX) stock jumped on Wednesday after the vaccine maker released results from a Phase 3 clinical trial of its COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine. The initial cohort results from this study included 'robust immune responses' for the CIC and flu vaccine that were comparable to licensed rivals Nuvaxovid and Fluzone HD. Confident Investing Starts Here: Additionally, Novavax noted that the two vaccines were well tolerated. Almost all of the adverse events, greater than 98%, that were experienced by patients were mild or moderate in severity. The trial includes roughly 2,000 patients aged 65 or older. Novavax stated that it will continue to seek partners to further the development of its CIC and stand-alone flu vaccines. The results from this study provide it with the data it needs for discussions with potential partners. NVAX Stock Movement Today While NVAX stock had soared more than 2% in pre-market trading, the company couldn't maintain those gains. As a result, the stock is only up 0.56% as of Wednesday morning. Investors will also note that shares are down 8.83% year-to-date and 54.6% over the past 12 months. The Phase 3 clinical trial data also failed to attract investor interest today. Trading volume was muted at 1.38 million shares, compared to a three-month daily average of roughly 11.29 million units. Is Novavax Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Novavax is Hold, based on one Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NVAX stock price target of $11.25, representing a potential 55.39% upside for the shares. Spark, TipRanks' AI analyst, highlighted 'strong revenue growth and profitability improvements' but warned of 'negative equity and cash flow challenges.'
Yahoo
21-05-2025
- Business
- Yahoo
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025. Stranahan cited that this will mitigate near-term risks. However, the analyst pointed out that the post-marketing commitments and the need for further trials are already considered in Novavax's guidance, indicating minimal influence on the stock's performance. A person holding a syringe filled with a vaccine, implying the companys impact on health and wellbeing. As the demand for COVID vaccines remains sizeable among older populations, the stricter labeling may not have a drastic impact on Nuvaxovid's potential market. Overall, the analyst maintains a neutral view on the stock, considering the full potential of Novavax's pipeline remains to be unlocked. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology firm that is engaged in the discovery, development, and commercialization of vaccines to protect against serious diseases worldwide. While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVAX and that has 100x upside potential, check out our report about this cheapest AI stock. Read Next: and . Disclosure. None. Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News
On May 19, JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company's COVID-19 vaccine, however with limitations. A closeup of a vial of the biotechnology company's vaccines. The analyst noted that they view the approval as a solid near-term win for Novavax, Inc. (NASDAQ:NVAX), highlighting the expected milestone payment of $225 million from Sanofi. However, the vaccine has been approved with a label for only older and high-risk adults and requires a post-marketing commitment for an additional phase 4 efficacy study. Management believes the incremental costs related to this will be neutral for the operating expenses through 2027. Joseph justified his Underweight rating on Novavax, Inc. (NASDAQ:NVAX) as he anticipates the vaccine sales to be minimal in 2025, and the company is viewing the year as educational/observational. Moreover, the analyst noted that this indicates that the vaccine's market reputation will not be visible until the second half of 2026, thereby making the FDA approval only a near-term win. While we acknowledge the potential of NVAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVAX and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine
Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval to its COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older. The shot, previously authorized for emergency use, also becomes commercially available for individuals aged 12 to 64 with underlying health conditions that heighten the risk of severe illness. Warning! GuruFocus has detected 4 Warning Signs with NVAX. Developed with Sanofi (NASDAQ:SNY), the protein-based vaccine is an alternative to existing mRNA options. Sanofi will now lead commercialization efforts and pay Novavax a $175 million milestone fee tied to the FDA's approval. Novavax expects additional revenue through future royalties as the vaccine rolls out in upcoming seasons. The company aims to begin commercial delivery of its 20252026 version this fall. CEO John Jacobs said demand could be robust, citing health data indicating older adults and those with medical vulnerabilities are most likely to seek seasonal COVID-19 shots. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine
Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval to its COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older. The shot, previously authorized for emergency use, also becomes commercially available for individuals aged 12 to 64 with underlying health conditions that heighten the risk of severe illness. Warning! GuruFocus has detected 4 Warning Signs with NVAX. Developed with Sanofi (NASDAQ:SNY), the protein-based vaccine is an alternative to existing mRNA options. Sanofi will now lead commercialization efforts and pay Novavax a $175 million milestone fee tied to the FDA's approval. Novavax expects additional revenue through future royalties as the vaccine rolls out in upcoming seasons. The company aims to begin commercial delivery of its 20252026 version this fall. CEO John Jacobs said demand could be robust, citing health data indicating older adults and those with medical vulnerabilities are most likely to seek seasonal COVID-19 shots. This article first appeared on GuruFocus. Sign in to access your portfolio
